Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2018-10-31

FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Dr.Reddys Laboratories Inc)

View source ↗

Summary

FDA approved a supplemental application for a generic buprenorphine/naloxone product (Dr. Reddy's Laboratories) under ANDA 205299. The approval supports the con…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Buprenorphine and naloxone (BUPRENORPHINE AND NALOXONE)

Snippet

SUPPL AP for BUPRENORPHINE AND NALOXONE (BUPRENORPHINE AND NALOXONE)